Amneal Pharmaceuticals AMRX

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.20 (+2.28%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Amneal Pharmaceuticals (AMRX)
    Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $8.9

    • Market Cap

      $2.76 Billion

    • Price-Earnings Ratio

      -23.42

    • Total Outstanding Shares

      309.97 Million Shares

    • Total Employees

      8,100

    • Dividend

      No dividend

    • IPO Date

      May 7, 2018

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Homepage

      https://www.amneal.com

    Historical Stock Splits

    If you bought 25 shares of AMRX before August 26, 2013, you'd have 1 share today.
    Execution DateSplit Amount
    August 26, 20131-for-25 (Reverse Split)

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$295.10 Million
    Net Cash Flow From Financing Activities$-211.79 Million
    Net Cash Flow From Investing Activities$-63.00 Million
    Net Cash Flow From Financing Activities, Continuing$-211.79 Million
    Net Cash Flow From Operating Activities$295.10 Million
    Exchange Gains/Losses$-999,000

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Cost Of Revenue$1.77 Billion
    Operating Income/Loss$249.33 Million
    Income Tax Expense/Benefit, Current$18.86 Million
    Other Operating Expenses$103.96 Million
    Research and Development$190.71 Million
    Diluted Average Shares$308.98 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Comprehensive Income/Loss Attributable To Parent$-33.16 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-150.05 Million
    Other Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$-76.17 Million
    Comprehensive Income/Loss Attributable To Parent$-150.05 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Noncurrent Liabilities$2.42 Billion
    Inventory$612.45 Million
    Other Non-current Liabilities$30.21 Million
    Other Non-current Assets$756.35 Million
    Liabilities$3.55 Billion
    Intangible Assets$732.38 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AMRX from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.